Clinical Trials Logo

Coronary Stenosis clinical trials

View clinical trials related to Coronary Stenosis.

Filter by:

NCT ID: NCT03101696 Completed - Clinical trials for Coronary Artery Stenosis of Unclear Hemodynamic Relevance

Determination of Coronarphysiological Parameters With the Method of Thermodillution

Start date: February 5, 2017
Phase:
Study type: Observational

The gold standard to induce coronary hyperemia for measurement of fractional flow reserve (FFR), coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) is adenosine, but it exerts several side effects due to its unspecific action on adenosine receptors. The specific A2a-receptor agonist, regadenoson, has been shown to dilate coronary arteries and enables FFR measurements. The aim of the study was to evaluate whether simultaneous measurement of FFR, CFR and IMR is feasible, safe and effective within regadenoson-induced hyperemia.

NCT ID: NCT03084367 Completed - Clinical trials for Coronary Artery Disease

Physiologic Assessment of Coronary Stenosis Following PCI

DEFINE PCI
Start date: June 20, 2017
Phase:
Study type: Observational

This is a pilot study designed to assess the relationship between iFR (instantaneous wave-free ratio) pullback and the distribution of coronary atheroma/stenoses as assessed by Quantitative Coronary Angiography (QCA) post angiographically successful PCI (Percutaneous Coronary Intervention).

NCT ID: NCT03054324 Recruiting - Coronary Stenosis Clinical Trials

Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis

FFRB
Start date: September 2, 2016
Phase:
Study type: Observational

Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing. Noninvasive assessment of FFR via a combination of computational fluid dynamics (CFD) and coronary CT angiography CCTA (the so-called FFRCT) has potential. Coronary computed tomographic angiography is a noninvasive test for diagnosis of anatomic coronary stenosis (i.e., narrowing of a blood vessel). A new analytical model of FFR from the general Bernoulli equation (conservation of energy) (FFRB) is simple and has potential. A collaborator group has recently developed a new analytical model to quantify pressure drop, and hence FFR, based on lesion dimensions (i.e., the cross-section area along the lesion and the length of lesion) and coronary flow, with no empirical parameters. The investigators hypothesize that this new model will allow quantification of FFR (FFRB) in a cohort of human patients with intermediate coronary stenosis. The study will compare FFRB with invasive FFR measurements from invasive coronary angiography (ICAG).

NCT ID: NCT03052803 Completed - Clinical trials for Coronary Artery Disease

Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries

FFR-DS
Start date: February 1, 2017
Phase: N/A
Study type: Observational

The aim of the study is to compare different devices available to measure fractional flow reserve (FFR) in coronary arteries.

NCT ID: NCT02985112 Recruiting - Clinical trials for Borderline Coronary Stenoses Assessment, Fractional Flow Reserve, Plaque Composition

INTegrated Assessment of intERmediate Coronary Stenoses by Fractional Flow rEserve (FFR) and Near-infraREd Spectroscopy (NIRS)

INTERFERE
Start date: March 2015
Phase: N/A
Study type: Observational [Patient Registry]

Revascularization of borderline coronary stenoses (40-70%) is usually driven by fractional flow reserve (FFR) which expresses the physiological significance of a lesion and tells the operator whether PCI may reduce the rate of adverse events as compared to medical therapy. Coronary stenoses with FFR value < 0.80 are indeed associated with a higher rate of adverse event and requires coronary revascularization whereas lesions with FFR > 0.80 show an excellent prognosis which cannot be improved by coronary stenting. Such a predictive value of FFR is theoretically based only on the degree of myocardial ischemia downstream from a given coronary stenosis: however, also plaque composition may play a crucial role in triggering future events especially in patients affected by acute coronary syndrome. Differences in plaque composition between FFR-positive and FFR negative lesions have never been assessed. Intracoronary Near-InfraRed Spectroscopy (NIRS) identifies lipid rich plaques that can potentially cause acute events. The aim of this study is to compare the lipid content expressed by LCBI (Lipid Core Burden Index) between functionally significant (FFR < 0.80) and non-significant (FFR > 0.80) stenoses in patients undergoing coronary angiography because of stable CAD and non-ST elevation acute coronary syndromes. This is an observational, prospective, multicentric study where we plan to collect 150 coronary lesions.

NCT ID: NCT02978456 Active, not recruiting - Coronary Disease Clinical Trials

Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation

GUIDE DES
Start date: February 23, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to compare clinical outcomes between quantitative coronary angiography -guided and Intravascular ultrasound -guided strategy in patients with significant coronary artery disease undergoing sirolimus-eluting Orsiro/Orsiro mission stent implantation.

NCT ID: NCT02951949 Completed - Atherosclerosis Clinical Trials

Estrogen Exposure and Atherosclerosis in Postmenopausal Women

Start date: November 2014
Phase:
Study type: Observational

One hundred Spanish postmenopausal women accepted to be investigated for cardiovascular risk actors including clinical features, serum biochemical parameters, single nucleotide polymorphisms for estrogen receptor, and imaging parameters, carotid intima-media thickness (91 women) and coronary computed tomography (32 women). Multivariable analysis confirmed that both age and glucose level directly affected IMT. Estrogenic exposure, as measured by the allele associated with lower expression of the ER beta gene, was protective at the sinus and the wall. Findings at the coronary arteries, either moderate or high calcium index (CAC) and/or significant lumen stenosis were sporadic and did not allow for establishing association with any of the variables assessed.

NCT ID: NCT02946320 Not yet recruiting - Clinical trials for Coronary Artery Stenosis

Optimal Predilatation Technique for BVS Implantation

OPTI-BVS
Start date: November 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the optimal way of predilatation for BVS implantation.

NCT ID: NCT02946307 Completed - Coronary Stenosis Clinical Trials

Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease

Start date: August 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of RESTORE Paclitaxel eluting balloon in the treatment of Chinese patients with coronary heart disease and small vessel lesions in comparison with RESOLUTE Zotarolimus eluting stent.

NCT ID: NCT02931331 Enrolling by invitation - Coronary Disease Clinical Trials

Coronary Revascularization Assessed by Stress PET

Start date: March 2016
Phase: N/A
Study type: Observational [Patient Registry]

Regional absolute myocardial blood flow during stress (sMBF) as measured by Positron Emission Tomography (PET) improves post mechanical revascularization provided there is a baseline stress induced perfusion defect. Coronary revascularization performed on regions without a stress induced perfusion defect does not increase the sMBF.